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Abstract
Background: Although micronutrient supplementation can reduce morbidity and mortality due to diarrhoea, 
nutritional influences on intestinal host defence are poorly understood. We tested the hypothesis that micronutrient 
supplementation can enhance barrier function of the gut.
Methods: We carried out two sub-studies nested within a randomised, double-blind placebo-controlled trial of daily 
micronutrient supplementation in an urban community in Lusaka, Zambia. In the first sub-study, gastric pH was 
measured in 203 participants. In the second sub-study, mucosal permeability, lipopolysaccharide (LPS) and anti-LPS 
antibodies, and serum soluble tumour necrosis factor receptor p55 (sTNFR55) concentrations were measured in 87 
participants. Up to three stool samples were also analysed microbiologically for detection of asymptomatic intestinal 
infection. Gastric histology was subsequently analysed in a third subset (n = 37) to assist in interpretation of the pH 
data. Informed consent was obtained from all participants after a three-stage information and consent process.
Results: Hypochlorhydria (fasting gastric pH > 4.0) was present in 75 (37%) of participants. In multivariate analysis, HIV 
infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 
0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective. 
Hypochlorhydria was associated with increased risk of salmonellosis. Mild (grade 1) gastric atrophy was found in 5 
participants, irrespective of Helicobacter pylori or HIV status. Intestinal permeability, LPS concentrations in serum, anti-
LPS IgG, and sTNFR55 concentrations did not differ significantly between micronutrient and placebo groups. Anti-LPS 
IgM was reduced in the micronutrient recipients (P <0.05).
Conclusions: We found evidence of a specific effect of HIV on gastric pH which was readily reversed by anti-retroviral 
therapy and not mediated by gastric atrophy. Micronutrients had a modest impact on gastric pH and one marker of 
bacterial translocation.
Trial Registration: Current Controlled Trials ISRCTN31173864
Background
Defence against infectious disease is a matter of the high-
est importance for the health and development of people
living in tropical regions. Diarrhoeal disease is a major
contributor to infectious disease morbidity and mortality
in developing countries especially in children and in
AIDS patients [1,2]. Malnutrition has long been associ-
ated with increased susceptibility to, and worse outcomes
from, infectious disease. In terms of diarrhoeal disease
micronutrients may be critical for robust host defence. In
particular, deficiency of vitamin A is associated with
increased mortality in children and the benefit of vitamin
A supplementation is probably at least partly attributable
to reduced mortality from diarrhoea [3]. There is con-
* Correspondence: m.p.kelly@qmul.ac.uk
1 Blizard Institute of Cell and Molecular Science, Barts & The London School of 
Medicine, Queen Mary University of London, London, UK
Full list of author information is available at the end of the articleKelly et al. BMC Gastroenterology 2010, 10:72
http://www.biomedcentral.com/1471-230X/10/72
Page 2 of 9
vincing evidence that zinc supplementation improves
outcomes in children with diarrhoea [4] and most trials
suggest that it reduces diarrhoea incidence when given
prophylactically [5,6]. In HIV infection there is mixed
evidence that micronutrient supplementation reduces
morbidity and mortality [7-9], and some evidence sug-
gests that selenium supplementation can raise CD4
counts in AIDS patients [10,11]. However, the mecha-
nisms by which micronutrients reduce the impact of diar-
rhoeal disease are entirely unknown. Evidence that
nutrition directly controls cell-mediated immunity has
been largely discredited [12], and there is no evidence
that nutritional interventions have an impact on humoral
immunity [13]. In view of the fact that vitamin A defi-
ciency is associated with breaches of epithelial barriers
[14] and zinc deficiency is associated with disorders of
Paneth and other intestinal epithelial cells [15], we
hypothesised that micronutrient affects barrier function
in the gut.
Bacterial translocation from the gut plays a major role
in infection, disease progression and mortality in cirrho-
sis [16-18], in hepatitis C [19], and in systemic sepsis syn-
drome [17]. Kupffer cells in the liver constitute the largest
compartment of macrophages in the body, presumably
there in order to deal with translocation, and there are
physico-chemical barriers to penetration and transloca-
tion which include gastric acid, the mucus layer, and the
integrity of the epithelial layer [20,21]. Gastrointestinal
barrier function therefore represents the sum of several
factors, and can only loosely be defined. At least one
component of this barrier, gastric acid (both in terms of
resting pH and pentagastrin-stimulated acid output) has
b e e n  k n o w n  f o r  m a n y  y e a r s  t o  b e  i m p a i r e d  i n  A I D S
[22,23].
It has been known for many years that HIV infection
leads to a severe T cell depletion in the intestinal mucosa
[24,25]. Recent data indicate that, at least in the SIV
model, this T cell population never recovers completely
[26] and it has been proposed that the enteropathy
observed in HIV infection leads to bacterial transloca-
tion, driving HIV disease progression [27]. We and oth-
ers, however, have shown that HIV-related enteropathy is
largely associated with the later stages of HIV infection
[28-34]. It seems likely that any intervention which could
ameliorate or reverse impaired barrier function in HIV
infected patients might reduce the systemic immune acti-
vation. T his immune activa tion is reflected in elevated
circulating cytokines such as interferon -γ and tumour
necrosis factor-α (TNF) which behave as predictors of
mortality in Zambian adults with AIDS [35]. As part of a
randomised, placebo-controlled trial of a daily multiple
micronutrient supplement [36], we studied several facets
of intestinal immunity and here we report our analysis of
gastric pH, intestinal permeability, LPS and TNF concen-
trations in serum.
Methods
Patients were studied during the course of a cluster-ran-
domised, placebo-controlled trial of daily micronutrients
supplementation in a community in Lusaka, Zambia. The
trial showed no evidence of benefit on diarrhoea inci-
dence or CD4 count, but severe episodes of diarrhoea and
mortality in HIV infection did appear to be reduced [36].
In summary, 500 adults with or without HIV infection
living in one section of Misisi, Lusaka, were recruited and
cluster-randomised by household. The multiple micronu-
trient (MM) supplement was designed to provide at least
the recommended nutrient intake [37] of 15 nutrients
(Table 1), and participants were crossed over to the oppo-
site treatment allocation after 2 years. The data were col-
l e c t e d  a t  a  t i m e  w h e n  h i g h l y  a c t i v e  a n t i - r e t r o v i r a l
treatment (HAART) was being introduced into Zambia
so some participants had been taking HAART for varying
periods of up to 15 months. Ethical approval was
o b t a i n e d  f r o m  t h e  R e s e a r c h  E t h i c s  C o m m i t t e e s  o f  t h e
University of Zambia and the London School of Hygiene
and Tropical Medicine. The trial was registered as
ISRCTN31173864.
The current study was nested within the main trial,
which was conducted from July 2003 to December 2006.
Two sub-studies were carried out on different groups of
participants identified at random during the course of the
main trial: (i) measurement of gastric pH (n = 203) in par-
ticipants who had been taking MM or placebo for
between 4 and 19 months (median 9 months, IQR 7-15
months); (ii) studies of intestinal permeability (using four
sugars), translocation (using LPS and anti-LPS antibod-
ies) and immune activation (using TNF receptor (TNFR)
p55) in 86 participants. The gastric pH and translocation
sub-studies were carried out at different times for logistic
reasons (i.e. workload), the pH study after the cross-over
and the translocation study before the cross-over, so
although permeability, LPS and TNF were assayed in the
same individuals on the same day, no before/after cross-
over comparisons within the same individual are avail-
able. The allocation of participants to the sub-studies was
largely at random, but the translocation study did include
18 participants who elected to undergo the permeability
testing rather than the endoscopy. As the treatment allo-
cation was carefully randomised and fully double-blind,
we anticipated that this would have no influence on the
results of the comparisons within each sub-study. Stool
samples (up to 3) were collected from each participant for
analysis of carriage of salmonellae and shigellae using
standard techniques.Kelly et al. BMC Gastroenterology 2010, 10:72
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Gastric pH measurements
To collect gastric acid, endoscopy was carried out in fast-
ing participants under sedation with midazolam. Aspi-
rates were collected by attaching a 10 ml syringe to the
biopsy port of a Pentax FG29W gastroscope which had
been carefully flushed with clean water and then air prior
to introduction. No aspiration was carried out until the
tip of the scope was in the pool of intra-gastric fluid. Gas-
tric pH was measured in aspirates of intra-gastric fluid
using Macherey-Nagel pH test strips which are accurate
to pH changes of 0.5 (D-52348, Macherey-Nagel, Ger-
many) to avoid contamination of pH probes.
Permeability: four sugar absorption/secretion testing
The four sugar test solution used contained 0.5 g xylose, 1
g rhamnose, 5 g lactulose and 0.2 g 3-O-methyl D-glucose
(Sigma chemicals, Poole, Dorset, UK) in 100 ml distilled
water to constitute an approximately isosmolar solution.
After collecting a pre-test sample to exclude prior inges-
tion of test sugars, participants drank this solution at time
0, and then urine samples were collected for exactly 5
hours and preserved with merthiolate (approximately
0.04% final concentration). Urine samples were frozen at -
80°C for transport and analysed by thin layer chromatog-
raphy as previously described [28,38]. Xylose recovery,
Rhamnose: 3-O-methyl D-Glucose (R:G) ratio, and
Lactulose: Rhamnose (L:R) ratio were analysed.
Lipopolysaccharide concentrations in serum
Lipopolysaccharide (LPS) and anti-lipopolysaccharide
antibodies (IgG and IgM) were measured as markers of
bacterial translocation. LPS concentrations in serum
were measured using the Pyrochrome-LAL kit (Associ-
ates of Cape Cod Inc, East Falmouth, MA) according to
the manufacturer's instructions and optimised for incu-
bation time which was determined to be 60 minutes.
Endotoxin core antibodies (EndoCAb) IgM and IgG were
measured by ELISA as previously described [39,40]. In
brief, polystyrene microplates were pre-coated with an
equimolar mixture of incomplete-core rough-mutant
endotoxins from each of four species of Gram-negative
bacteria, complexed with polymyxin B. An eight-point
standard curve was constructed using doubling dilutions
of a pooled serum calibrated in EndoCAb median units,
where 100 (%) was the median value for IgG or IgM in
1,000 healthy Scottish adults. Test and control samples
were diluted 1:200 with dilution buffer and 100 μL of each
sample added in triplicate to the plate and incubated for 1
h at 37C. After washing three times with wash buffer
(Dulbecco phosphate buffered saline containing 0.1% [v/
v] Tween 20), 100 μL of a diluted alkaline phosphatase
conjugated goat antihuman IgG or IgM antibody was
added to each well. After incubation for 1 h at 37C the
plates were washed three times with wash buffer then
once with distilled water and blotted dry. Substrate (100
μL per well), comprising 1 mg/ml disodium p-nitrophe-
nylphosphate dissolved in 1 M diethanolamine buffer
with 0.5 mM magnesium chloride, was added and the
plate incubated at room temperature in the dark for 20-
30 min. The reaction was stopped with 50 μL per well of 2
M sodium hydroxide and read at 405 nm.
Tumour necrosis factor receptor p55 concentrations
In order to look for correlation between LPS or anti-LPS
antibodies and macrophage activation, we measured
TNFR (p55) in the same sera which were assayed for LPS
and anti-LPS. TNFR was measured by ELISA (R&D sys-
Table 1: Composition of the micronutrient tablet
Micronutrient Amount RNI37
β-carotene 4.8 mg 4.2 mg equivalent
Ascorbic acid (vitamin C) 70 mg 40 mg
Cholecalciferol (vitamin D3)5  μ g -
Tocopherol (vitamin E) 10 mg 4 mg (uncertain)
Thiamine (vitamin B1) 1.4 mg 1.0 mg
Riboflavin (vitamin B2) 1.4 mg 1.3 mg
Niacin 18 mg 17 mg
Pyridoxine (vitamin B6) 1.9 mg 1.4 mg
Cyanocobalamin (vitamin B12) 2.6 μg 1.5 μg
Folic acid 400 μg 200 μg
Iron 30 mg 14.8 mg (women), 
8.7 mg (men)
Zinc 15 mg 9.5 mg
Copper 2 mg 1.2 mg
Selenium 65 μg 75 μg
Iodine 150 μg 140 μg
Composition of the trial medication (one tablet was given each day) 
compared to the UK recommended nutrient intake (RNI). The RNI for 
vitamin D in healthy adults exposed to sunlight is zero if appropriate 
lipid precursors are present in the diet [37].Kelly et al. BMC Gastroenterology 2010, 10:72
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tems, Abingdon, UK) according to the manufacturer's
instructions.
Assessment of gastric histology
When it became apparent that HIV was associated with
hypochlorhydria, we submitted for histological examina-
tion gastric biopsies from antrum and fundus from 10
HIV infected and 27 uninfected participants from the
same study cohort obtained during an earlier study of
Helicobacter pylori and HIV [41]. Of these, 3 had CD4
counts under 200 cells/μl, all of whom were investigated
prior to receiving treatment with anti-retroviral drugs.
Haematoxylin and eosin-stained sections were assessed
using the modified Sydney system for evaluating gastric
changes related to Helicobacter pylori [42]. Extent of
intestinal metaplasia was assessed by staining with Alcian
blue - Periodic Acid Schiff's (AB-PAS). Density of Helico-
bacter pylori staining was assessed using a modified
Giemsa stain [43]. The Modified Sydney System utilises a
0-3 range score across 4 domains as previously described.
For atrophy the score ranges from 0 (normal gland struc-
ture), 1 (minimal gland loss), 2 (moderate gland loss or
replacement with a chronic inflammatory infiltrate) and 3
(severe gland loss/few glands seen).
Data analysis
Hypochlorhydria was defined as fasting gastric pH > 4.0.
Variables are presented as median and interquartile range
(IQR) and non-parametric statistics were used (Kruskal-
Wallis test for comparison of two medians, and correla-
tion coefficients were calculated on log-transformed
data). Statistical analysis was carried out using STATA 10
(Stata Corp, College Station, Texas).
Sample size calculations were performed post hoc as
this was a sub-group analysis of a clinical trial with diar-
rhoea as the primary endpoint [36]. Reference to pub-
lished work [44] indicates that LPS concentrations in
AIDS patients might be expected around 60 pg/ml and in
controls around 30 pg/ml. To detect a difference between
these means, with standard deviation of 44 pg/ml as
observed here and with 80% power at 95% confidence,
would require 34 in each group.
Results
The assessments of barrier function reported here were
performed on subsets of the larger trial group, all of
whom were randomly allocated to micronutrient or pla-
cebo supplementation in a double-blind manner; the
demographic characteristics of these subsets are shown
in Table 2.
Gastric pH was reduced at all stages of HIV infection
In 203 participants in whom pH was measured in fasting
gastric aspirates, the median pH was 3 (IQR 1-5.5).
Hypochlorhydria was present in 75 (37%). Of the 72 par-
ticipants with hypochlorhydria whose HIV status was
known, 42 were HIV seropositive (OR 3.1, 95%CI 1.6-5.9;
P = 0.0003). Anti-retrovirals were being taken by 14 par-
ticipants at the time of the analysis, so the relationship
between gastric pH and HIV status was further assessed
by breaking down HIV infected participants into three
groups: HIV positive with high CD4 count (>200 cells/μl),
HIV positive with low CD4 count (200 cells/μl or less),
and HIV positive taking HAART (all except one of whom
had CD4 counts < 200 cells/μl when initiated). HIV infec-
tion was associated with hypochlorhydria, but not in
patients taking HAART (Figure 1). The proportion of
participants with hypochlorhydria was 29/114 (25%) in
the HIV negative group, 36/62 (58%) in the HIV positive
group with higher CD4 counts, 4/8 (50%) in the HIV pos-
itive group with low CD4 count, and 3/14 (21%) in the
group taking anti-retrovirals. Intestinal infection with
two species of pathogenic bacteria was more likely in
hypochlorhydric patients: Salmonella enterica serovar
typhimurium and/or Shigella spp. infections were found
in 11/198 (5%) of samples from participants with
hypochlorhydria compared with 7/357 (2%) of samples
from those without (P < 0.05).
Gastric pH was decreased by MM supplementation in 
multivariate analysis
Participants had been taking MM or placebo for a median
of 9 (IQR 7-15) months, but the duration of consumption
of trial medication had no effect on pH. Median (IQR) pH
was 2.3 (1-5) in 100 participants allocated to MM and 3
(1-5.5) in 103 allocated to placebo (P = 0.31). Hypochlo-
rhydria was found in 32 (32%) participants on MM and 43
(42%) on placebo (P  = 0.19). Multivariate analysis was
carried out using logistic regression with hypochlorhy-
dria as the dependent variable, and including age, sex, low
body mass index, HIV infection, low CD4 count, taking
HAART, and treatment allocation. In the final model,
HIV infection (OR 4.1, 95%CI 2.2-7.8; P  < 0.001) was
associated with hypochlorhydria; taking HAART (OR
0.16, 0.04-0.67; P = 0.01) and allocation to micronutrient
supplementation (OR 0.53, 0.28-0.99; P < 0.05) were pro-
tective against it. Low BMI (18.5 kg/m2 or less) was not
predictive of hypochlorhydria and did not explain the
association between HIV and hypochlorhydria.
Intestinal permeability was not reduced by MM 
supplementation
Four sugar testing and fractional urine recovery over 5
hours was used to obtain measurements of Xylose
absorption, Rhamnose:3-O-methyl D-Glucose absorp-
tion ratio, and Lactulose:Rhamnose permeation ratio in a
subset of 87 participants drawn at random from the
larger group. Of these participants, only one had a CD4
count below 200 cells/μl and none were taking anti-retro-Kelly et al. BMC Gastroenterology 2010, 10:72
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viral drugs. These three measures of intestinal function
and permeability did not differ in MM compared to pla-
cebo groups (Table 3). Neither was there any significant
difference between HIV groups (Table 3).
Anti-LPS IgM was reduced by MM supplementation
LPS was assayed in sera from the same 87 participants
undergoing permeability testing as above. LPS concentra-
tions did not differ in MM and placebo groups, nor was
there any difference between HIV seropositive and HIV
seronegative participants (Table 3). No such differences
were observed in anti-LPS IgG in serum either. However,
anti-LPS IgM was significantly reduced in micronutrient
recipients (Table 3). No significant correlation was found
between LPS or anti-LPS levels in serum and the gut
absorption or permeability markers, with the exception of
log-transformed xylose recovery which was negatively
correlated with log-transformed anti-LPS IgG (r = -0.30;
P = 0.006).
TNFR was not reduced by MM but was correlated with anti-
LPS IgM
TNFR was measured as receptor p55, again in the same
sera in which LPS and anti-LPS antibodies were assayed.
No difference was observed either by treatment alloca-
tion or by HIV status (Table 3). The correlation between
measures of translocation and TNFRp55 was also exam-
ined (Figure 2). The correlation coefficient between log-
transformed TNFRp55 and anti-LPS IgM was significant
(r  = 0.30, P  = 0.006), as was the correlation between
TNFRp55 and anti-LPS IgG (r = 0.27, P = 0.01). Using
multiple linear regression to define which immunoglobu-
lin class was more strongly correlated with TNF activa-
tion, the IgM was significant associated with TNFRp55
while the IgG was not.
HIV-related hypochlorhydria is not due to gastric atrophy
In order to examine the mechanism of the hypochlorhy-
dria, histological examination of antral and fundal gastric
tissue was performed on 37 patients. No evidence of
intestinal metaplasia was found, even though all except 4
(3 HIV seropositive, 1 HIV seronegative) had positive
serology for H. pylori, and Helicobacter-like organisms
were visible in 30 out of the 37 histological sections (den-
sity recorded as low in 8, intermediate in 14, and high in
8). All Helicobacter-infected gastric mucosa showed
some evidence of gastritis. Gastric atrophy of mild grade
was observed in biopsies from 5 participants (3 HIV sero-
positive, 2 HIV seronegative; P = 0.11), all of whom were
seropositive for H. pylori. No moderate or severe gastric
atrophy was observed (Figure 3).
Discussion and Conclusions
In this study we examined several components of the gas-
trointestinal barrier against translocation of bacteria and
their products, in relation to HIV status and to micronu-
Table 2: Demographic and clinical characteristics of study groups for the analysis of gastric acid and the analysis of 
permeability, translocation and immune activation
Gastric acid sub-group Translocation sub-group
MM Placebo MM Placebo
(n = 100) (n = 103) (n = 38) (n = 49)
Age (yrs) (median, 5th/95th centiles) 31 (19-65) 36 (20-62) 41 (19-56) 29 (18-51)
Sex Male 35 48 8 14
Female 65 55 30 35
BMI (kg/m2) (median, 5th/95th centiles) 21.3 (17.9-31.7) 21.9 (17.7-31.6) 22.1 (18.3-36.3) 23.2 (18.0-41.6)
MUAC (cm) (median, 5th/95th centiles) 28.0 (24.0-38.0) 27.4 (23.0-34.3) 26.0 (22.5-37.0) 26.8 (21.9-38.2)
HIV positive 40 of 97 tested 44 of 101 tested 5 of 29 tested 12 of 46 tested
CD4 count (median, 5th/95th centiles) 382 (68-716) 349 (161-659) 362 (331-634) 466 (190-936)
CD4 count < 200 cells/μL 7/40 4/44 0/5 2/12
P values are not shown: none of the comparisons between MM and placebo were significant
Figure 1 Gastric pH in relation to HIV status and anti-retroviral 
therapy. The difference across all groups was significantly different us-
ing the Kruskal-Wallis test (P = 0.0005).
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trient supplementation. We found that hypochlorhydria
in fasted adults was associated with HIV infection irre-
spective of stage, reversed by anti-retroviral therapy and,
when adjusted for HIV status in multivariate analysis,
reduced by micronutrient supplementation. Although a
large body of work has defined hypochlorhydria in terms
of gastric acid secretion rate, in this study we only exam-
ined gastric pH in one fasting aspirate obtained by endos-
copy. While our single fasting sample is almost certainly
not as sensitive in detecting hypochlorhydria as measure-
ment of acid secretion rate would be, it is relevant to
infectious disease as a snapshot of gastric pH represents
the chemical barrier encountered by a pathogen on inges-
tion. Impaired gastric pH was associated with asymptom-
atic colonisation by two potentially pathogenic bacterial
species, confirming the relevance of this way of analysing
gastric pH for this situation.
We found little evidence that micronutrient supple-
mentation reduced markers of intestinal permeability or
bacterial translocation, except for a reduction in anti-LPS
IgM concentrations in serum which just reached statisti-
cal significance. Interestingly, the anti-LPS IgM was
clearly correlated with TNF pathway activation, implying
that translocation is indeed a determinant of systemic
Table 3: Measures of intestinal permeability, absorptive capacity, bacterial translocation, and tumour necrosis factor 
receptor p55, analysed both by treatment allocation and by HIV status
Measure By treatment allocation By HIV status*
MM Placebo P HIV positive HIV negative P
(n = 37) (n = 49) (n = 17) (n = 57)
Xylose (%) 21.4 (18.9-27.4) 21.2 (16.3-26.4) 0.49 20.3 (17.9-23.7) 21.2 (15.4-27.4) 0.94
R:G 0.35 (0.32-0.40) 0.38 (0.34-0.42) 0.23 0.39 (0.35-0.43) 0.36 (0.32-0.41) 0.12
L:R 0.057 (0.045-0.088) 0.048 (0.036-0.071) 0.12 0.059 (0.036-0.071) 0.050 (0.036-0.077) 0.49
LPS (pg/ml) 50.7 (24.8-115.1) 51.6 (22.0-107.9) 0.52 64.7 (29-113) 51.6 (20-109) 0.56
anti-LPS IgM (units) 95 (58-148) 127 (100-175) 0.047 117 (89-134) 118 (66-190) 0.46
anti-LPS IgG (units) 115 (63-201) 152 (64-272) 0.60 142 (98-293) 153 (63-223) 0.33
TNFp55 (pg/ml) 1.13 (1.01-1.40) 1.22 (1.02-1.40) 0.62 1.32 (0.99-1.64) 1.14 (1.04-1.38) 0.37
* HIV testing was declined by 12 participants. The units given for anti-LPS antibodies are in reference to Scottish blood donor median value (see 
Methods).
Figure 2 Correlation between serum concentrations of TNFR55 
and anti-LPS IgM. The correlation coefficient (r = 0.30, P = 0.006) was 
derived from log-transformed data.
Figure 3 Gastric histology. Representative histological sections from 
gastric biopsies from a patient with (A) normal gastric histology and (B) 
the most severe gastric atrophy observed, which was classified as mild. 
No moderate or severe atrophy was seen.
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immune activation in the mixed HIV/tropical enteropa-
thy present in this population. Although anti-LPS IgM
was reduced in the MM group, TNFR was not, and it may
be that a larger reduction in translocation is required
before an effect on TNF pathway activation is detectable.
We previously noted [36] that our intervention had only
modest effect on blood measures of vitamin A and zinc,
even though the erythrocyte folate response was good,
and we speculate that higher doses of micronutrients may
have an enhanced effect.
We do not yet have an explanation for our findings that
HIV infection is associated with hypochlorhydria. We
had speculated prior to this study that hypochlorhydria
would be attributable to malnutrition (low BMI) but this
was not the case. Other workers have previously reported
changes in parietal cell morphology [22] but we found
minimal evidence of gastric atrophy and we propose that
it is due to a specific effect of HIV itself, or perhaps
through cytokine secretion, on the parietal cell. We have
previously shown that HIV infection is associated with
reduced peptic ulceration in Zambian adults co-infected
with Helicobacter pylori infection [41], which may well be
explained by the hypochlorhydria we report here, but the
cellular and molecular nature of the interaction between
HIV and H. pylori needs further work. Unlike increased
permeability, hypochlorhydria seems to occur at any
stage of HIV disease.
In addition to the effect of hypochlorhydria on intesti-
nal infection reported here, and an effect on bacterial
overgrowth previously reported [23], it might be
expected to lead to impaired nutrient absorption, espe-
cially iron which is preferentially absorbed in the Fe2+
form. Gastric acid converts Fe3+ to Fe2+. Iron deficiency in
children has been reversed by H. pylori eradication
[45,46], although in another study there was no difference
in fractional absorption of iron from a test meal in
hypochlorhydric children [47]. The impact of HIV-
related hypochlorhydria on iron metabolism remains to
be established.
Recent data [27,44] have given fresh support to the
hypothesis that in HIV infection increased intestinal per-
meability is responsible for bacterial translocation and
systemic immune activation. Although we found a signif-
icant correlation between anti-LPS IgM (a marker of bac-
terial translocation) and TNFRp55, we found no
correlation between permeability and translocation
markers. One possible explanation for this is that back-
ground tropical enteropathy [28,38] allows translocation
in the absence of HIV, perhaps by mechanisms other than
paracellular permeability. The median LPS concentration
in serum in the HIV negative participants in our current
study (51 pg/ml) was similar to that found in chronic HIV
infection in the American study and much higher than
the HIV seronegative participants in that study (approxi-
mately 30 pg/ml) [44]. Alternatively, it may be that lactu-
lose permeation is not an appropriate measure of
permeability for assessing risk of bacterial translocation,
a s  i t  r e fl e c t s  a  m u c h  s m a l l e r  p o r e  s i z e  t h a n  w o u l d  b e
required to permit translocation of bacteria or even LPS.
Lactulose is an imperfect marker of small intestinal 'leak-
iness' but in the absence of non-invasive alternatives it
has been widely used [38]. There are no widely used
markers of colonic 'leakiness', which is a major weakness
when it comes to understanding translocation. A third
explanation is that bacterial translocation due to
increased intestinal permeability is mainly a feature of
advanced HIV infection. In a previous study of intestinal
p e r m e a b i l i t y  w e  f o u n d  t h a t  p e r m e a b i l i t y  w a s  o n l y  e l e -
vated in HIV infected adults with low CD4 counts [28].
Only one of the participants we assessed here had a CD4
count below 200 cells/μL. Previous studies, with few
exceptions [48,49], mostly show that HIV enteropathy is
associated with late-stage disease [28-34]. There are few
data from populations where tropical enteropathy is pres-
ent, but our previous data from Zambia and older data
from Uganda [50] support the idea that there is little dif-
ference in permeability between early HIV and tropical
enteropathy.
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